Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment

Tarancón, R. ; Mata, E. (Universidad de Zaragoza) ; Uranga, S. (Universidad de Zaragoza) ; Gómez, A.B. (Universidad de Zaragoza) ; Marinova, D. (Universidad de Zaragoza) ; Otal, I. (Universidad de Zaragoza) ; Martín, C. (Universidad de Zaragoza) ; Aguiló, N. (Universidad de Zaragoza)

Resumen: Background: Substantial recent advances in the comprehension of the molecular and cellular mechanisms behind asthma have evidenced the importance of the lung immune environment for disease outcome, making modulation of local immune responses an attractive therapeutic target against this pathology. Live attenuated mycobacteria, such as the tuberculosis vaccine BCG, have been classically linked with a type 1 response, and proposed as possible modulators of the type 2 response usually associated with asthma.
Methods: In this study we used different acute and chronic murine models of asthma to investigate the therapeutic efficacy of intranasal delivery of the live tuberculosis vaccines BCG and MTBVAC by regulating the lung immune environment associated with airway hyperresponsiveness (AHR).
Findings: Intranasal administration of BCG, or the novel tuberculosis vaccine candidate MTBVAC, abrogated AHR-associated hallmarks, including eosinophilia and lung remodeling. This correlated with the re-polarization of allergen-induced M2 macrophages towards an M1 phenotype, as well as with the induction of a strong allergen-specific Th1 response. Importantly, vaccine treatment was effective in a scenario of established chronic asthma where a strong eosinophil infiltration was already present prior to immunization. We finally compared the nebulization efficiency of clinical formulations of MTBVAC and BCG using a standard commercial nebulizer for potential aerosol application.
Interpretation: Our results demonstrate that pulmonary live tuberculosis vaccines efficiently revert established asthma in mice. These data support the further exploration of this approach as potential therapy against asthma.

Idioma: Inglés

DOI: 10.1016/j.ebiom.2020.103186

Año: 2021

Publicado en: EBioMedicine (2021), 103186 [14 pp]
ISSN: 2352-3964

Factor impacto JCR: 11.205 (2021)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 14 / 140 = 0.1 (2021) - Q1 - T1

Factor impacto CITESCORE: 15.0 - Medicine (Q1) - Biochemistry, Genetics and Molecular Biology (Q1)

Factor impacto SCIMAGO: 2.663 - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII-DGA-FSE-UZ/JIUZ-2018-BIO-01
Financiación: info:eu-repo/grantAgreement/ES/MCIU/RTI2018-097625-B-I00
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Proy. investigación HQA (Dpto. Microb.Ped.Radio.Sal.Pú.)